CN Patent

CN115850240B — 一种治疗急性髓系白血病药物奥卢他西尼的合成方法

Assigned to Beijing Kang Lisheng Pharmaceutical Technology Development Co ltd · Expires 2023-09-19 · 3y expired

What this patent protects

本发明公开了一种奥卢他西尼的合成方法，采用(3S)‑3‑氨基丁酸乙酯、5‑氟‑1‑甲基‑6‑氧代‑1，6‑二氢吡啶‑2‑腈以及2‑氨基‑5‑氯‑苯甲醛为起始原料，经反应得到高光学纯度和化学纯度的奥卢他西尼。

USPTO Abstract

本发明公开了一种奥卢他西尼的合成方法，采用(3S)‑3‑氨基丁酸乙酯、5‑氟‑1‑甲基‑6‑氧代‑1，6‑二氢吡啶‑2‑腈以及2‑氨基‑5‑氯‑苯甲醛为起始原料，经反应得到高光学纯度和化学纯度的奥卢他西尼。

Drugs covered by this patent

Patent Metadata

Patent number
CN115850240B
Jurisdiction
CN
Classification
—
Expires
2023-09-19
Drug substance claim
No
Drug product claim
No
Assignee
Beijing Kang Lisheng Pharmaceutical Technology Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.